Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Carcinoma (NEC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)UnknownNCT02687958
What this trial is testing

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Who this might be right for
Neuroendocrine Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica 30
Testing effectiveness (Phase 2)Looking for participantsNCT06893783
What this trial is testing

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Who this might be right for
Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of PancreasNeuroendocrine Carcinoma of Prostate
Inkeun Park 60
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Testing effectiveness (Phase 2)Looking for participantsNCT06503146
What this trial is testing

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Who this might be right for
SarcomaSmall Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)Mesothelioma+7 more
National Cancer Institute (NCI) 320
Testing effectiveness (Phase 2)Study completedNCT03837977
What this trial is testing

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

Who this might be right for
OncologyNeuroendocrine Carcinoma
The Christie NHS Foundation Trust 58
Testing effectiveness (Phase 2)Looking for participantsNCT07518602
What this trial is testing

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Sun Yat-sen University 34